Last reviewed · How we verify
formoterol - beclometasone
At a glance
| Generic name | formoterol - beclometasone |
|---|---|
| Also known as | FOSTER |
| Sponsor | Università degli Studi di Brescia |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)
- VENTURI (VENTilation Using Respiratory Imaging) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- formoterol - beclometasone CI brief — competitive landscape report
- formoterol - beclometasone updates RSS · CI watch RSS
- Università degli Studi di Brescia portfolio CI